跳至主要内容
临床试验/NCT00185354
NCT00185354已完成3 期

Multi-center, Open, Randomized, Parallel Group Comparison of Cycle Control for Seven Cycles and Endometrial Safety in a Subgroup for Thirteen Cycles of Contraceptive Patch SH P00331F (0.9 mg Ethinylestradiol/1.9 mg Gestodene) vs. a Contraceptive Comparator Patch (0.6 mg Ethinylestradiol/6 mg Norelgestromin) in 400 Healthy Female Volunteers

Bayer0 个研究点目标入组 422 人开始时间: 2004年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Bayer
入组人数
422
主要终点
Number of pregnancies

研究概览

简要总结

The purpose of this study is to compare bleeding pattern and safety of contraceptive patch SH P00331F to a marketed comparator.

详细描述

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Healthy female volunteer aged 18-35, smokers 18-30

排除标准

  • Contraindications for using hormonal contraceptives

研究组 & 干预措施

Arm 2

Active Comparator

干预措施: SH P00331N (Drug)

Arm 1

Experimental

干预措施: BAY86-5016, SH P00331F (Drug)

结局指标

主要结局

Number of pregnancies

时间窗: 13 cycles

Bleeding pattern and cycle control

时间窗: 13 cycles

次要结局

  • Adverse events collection(13 cycles)
  • Physical and gynecological exam(13 cycles)
  • Endometrial biopsy(13 cycles)

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

相似试验